Results 71 to 80 of about 105,478 (251)

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT

Health Technology Assessment, 2019
Background: Oxaliplatin and fluoropyrimidine chemotherapy administered over 6 months is the standard adjuvant regimen for patients with high-risk stage II or III colorectal cancer.
Timothy Iveson, Kathleen A Boyd, Rachel S Kerr, Jose Robles-Zurita, Mark P Saunders, Andrew H Briggs, Jim Cassidy, Niels Henrik Hollander, Josep Tabernero, Andrew Haydon, Bengt Glimelius, Andrea Harkin, Karen Allan, John McQueen, Sarah Pearson, Ashita Waterston, Louise Medley, Charles Wilson, Richard Ellis, Sharadah Essapen, Amandeep S Dhadda, Mark Harrison, Stephen Falk, Sherif Raouf, Charlotte Rees, Rene K Olesen, David Propper, John Bridgewater, Ashraf Azzabi, David Farrugia, Andrew Webb, David Cunningham, Tamas Hickish, Andrew Weaver, Simon Gollins, Harpreet Wasan, James Paul   +36 more
doaj   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Completion vs. early discontinuation of chemotherapy and the impact on 5‐year all‐cause mortality in women treated for early‐stage breast cancer from 2015 to 2020: A cohort study using a target trial emulation approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Chemotherapy is given for early‐stage breast cancer; however, some patients discontinue before completing all planned cycles. This study investigated the impact of early chemotherapy discontinuation on treatment outcomes. Methods This retrospective cohort study used a target trial emulation framework to conduct a causal analysis of the all‐
Luke Steventon, Chengsheng Ju, Kenneth K. C. Man, Rebecca Roylance, Diego Ottaviani, Chiara Creed, Michal Sladkowski, Alec Wisner, Li Wei, Pinkie Chambers   +9 more
wiley   +1 more source

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross‐sectional analysis

British Journal of Clinical Pharmacology, EarlyView.
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar, Chloe Ratcliffe, Videha Sharma, William G. Newman, Munir Pirmohamed, John McDermott   +5 more
wiley   +1 more source

Protective Effect of Oleuropein on 5-Fluorouracil-Induced Ovarian Damage [PDF]

Journal of Ardabil University of Medical Sciences
Background: 5-fluorouracil is one of the chemotherapy drugs that has destructive effects on body tissues such as the heart, liver, kidney, brain and reproductive system in humans and animals. Reproductive dysfunction is considered to be an important side
Mahshid Khajavi, Elham Safarzadeh, Faraz Mahdizadeh, Shokofeh Banaei   +3 more
doaj  

Chemotherapeutic Potential of Fluorouracil‐Platinum (IV) Prodrugs Against Cisplatin‐Resistant Colorectal Cancer Cells

Chemistry – A European Journal, EarlyView.
ABSTRACT Fluorouracil‐platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs PtIVP‐5FUMeOBut and PtIV56‐5FUMeOBut were actualized by derivatising the clinical drug 5‐fluorouracil (5FU) and coordinating it to platinum(IV) complexes, leveraging the established cytotoxicity of ...
Maria George Elias, Aleen Khoury, Shadma Fatima, Timothy J. Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P. Gordon, Kieran F. Scott, Janice R. Aldrich‐Wright   +9 more
wiley   +1 more source

Impact of Infratemporal Fossa Clearance on Survival in Advanced Buccal Mucosa Cancers

Head &Neck, EarlyView.
ABSTRACT Introduction Buccal mucosa cancers are the most prevalent oral cavity cancers in South Asia, often attributed to widespread tobacco use. The current NCCN guidelines generally advise against primary surgery for locally very advanced (cT4b) buccal cancers involving the masticatory space and infratemporal fossa (ITF).
Sudhir Nair, Rathan Shetty, Amit Bhawalkar, Poonam Joshi, Arjun Singh, Hitesh Singhavi, Jitendra Kumar Sharma, Shwetabh Sinha, Anuj Kumar, Sarbani Ghosh Laskar, Amit Joshi, Pankaj Chaturvedi   +11 more
wiley   +1 more source

Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis

Frontiers in Public Health
BackgroundThe incidence of gall bladder cancer (GBC), one of the most prevalent bile duct malignancies, differs with ethnicity and geographic location. To treat unresected GBC in the Chinese setting, this study aimed to assess the financial effectiveness
Zhaoyan Chen, Fangyuan Tian
doaj   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Adherance to approved protocol chemotherapy for breast cancer at Songklanagarind Hospital

Journal of Health Science and Medical Research (JHSMR), 2002
At Songklanagarind Hospital, a protocol for chemotherapy in breast cancer has been used since 1994. The purpose of this study was to examine "non-medical" factors that may reflect non-acceptance of this protocol.
W Achanond, K Tangkietgumjai, T Ovartlarnporn, J Prukpitikul, A Naulsri, W Leelasamran, D Supawatanawong, U Wongsatit   +7 more
doaj